dc.creator | Rey, E. | es |
dc.creator | Ampuero Herrojo, Javier | es |
dc.creator | Molina-Jiménez, F. | es |
dc.creator | García-García, Y. | es |
dc.creator | Muñoz Hernández, Rocío | es |
dc.creator | Romero Gómez, Manuel | es |
dc.creator | García-Monzón, C. | es |
dc.creator | Majano, P. | es |
dc.creator | González-Rodríguez, A. | es |
dc.date.accessioned | 2022-11-09T14:24:37Z | |
dc.date.available | 2022-11-09T14:24:37Z | |
dc.date.issued | 2021-01-12 | |
dc.identifier.citation | Rey, E., Ampuero Herrojo, J., Molina-Jiménez, F., García-García, Y., Muñoz Hernández, R., Romero Gómez, M.,...,González-Rodríguez, A. (2021). Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation. Clinical and translational medicine, 11 (1), e275. https://doi.org/10.1002/ctm2.275. | |
dc.identifier.issn | 2001-1326 | es |
dc.identifier.uri | https://hdl.handle.net/11441/139181 | |
dc.description.abstract | In the present study, we have demonstrated that sofos buvir (SOF) treatment improves systemic insulin resis tance in hepatitis C virus (HCV)-patients, and, for the first
time, revealed which molecular mechanisms are involved
in SOF effects on the impaired insulin response induced by
HCV in hepatocytes. | es |
dc.format | application/pdf | es |
dc.format.extent | 5 p. | es |
dc.language.iso | eng | es |
dc.publisher | WILEY | es |
dc.relation.ispartof | Clinical and translational medicine, 11 (1), e275. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | ALT | es |
dc.subject | ApoB | es |
dc.subject | Glycated hemoglobin | es |
dc.title | Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.projectID | PI16/00823 | es |
dc.relation.projectID | PI17/0535 | es |
dc.relation.projectID | PI17/0008 | es |
dc.relation.publisherversion | https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctm2.275 | es |
dc.identifier.doi | 10.1002/ctm2.275 | es |
dc.journaltitle | Clinical and translational medicine | es |
dc.publication.volumen | 11 | es |
dc.publication.issue | 1 | es |
dc.publication.initialPage | e275 | es |
dc.contributor.funder | Instituto de Salud Carlos III | es |
dc.contributor.funder | European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER) | es |